Related Experiment Video

Updated: Aug 19, 2026

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

[Preventing effect of angiotensin II receptor blocker on neointimal hyperplasia after vascular injury]

Masaaki Miyata1, Hideyuki Eto, Sadatoshi Biro

  • 1First Department of Internal Medicine, Faculty of Medicine, Kagoshima University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|October 26, 2002
PubMed

Insights

Angiotensin II receptor blockers may prevent restenosis after angioplasty procedures like percutaneous transluminal coronary angioplasty (PTCA). These drugs show promise in reducing neointimal hyperplasia and in-stent restenosis rates.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Context:

  • Percutaneous transluminal coronary angioplasty (PTCA) and stent implantation are common treatments for coronary atherosclerosis.
  • Vascular restenosis remains a significant limitation to the long-term success of these procedures.

Purpose:

  • To evaluate the efficacy of angiotensin II receptor blockers (ARBs) in preventing vascular restenosis after angioplasty.
  • To compare ARBs with ACE inhibitors in preclinical and clinical settings for restenosis prevention.

Summary:

  • While ACE inhibitors like cilazapril showed limited success in human PTCA studies, ARBs such as candesartan and valsartan demonstrated efficacy in inhibiting neointimal formation and reducing in-stent restenosis in preclinical and clinical trials.
  • These findings suggest that inhibiting the renin-angiotensin system via ARBs may be a viable strategy to prevent restenosis post-angioplasty.

Impact:

  • Provides evidence supporting the use of ARBs as a therapeutic strategy to improve long-term outcomes after coronary angioplasty and stenting.
  • Highlights the differential efficacy of renin-angiotensin system inhibitors in preventing vascular restenosis, guiding future clinical practice and research.

More Related Videos

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics08:42

A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics

Published on: September 19, 2016

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application06:53

A Rat Carotid Artery Pressure-Controlled Segmental Balloon Injury with Periadventitial Therapeutic Application

Published on: July 9, 2020

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...